← Browse by Condition

Medical Condition

non hodgkin lymphoma

Total Trials

16

Recruiting Now

16

Trial Phases

Phase 1, Phase 2, EARLY_Phase 1

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — non hodgkin lymphoma Clinical Trials

How many clinical trials are currently recruiting for non hodgkin lymphoma?

ClinicalMetric currently tracks 16 actively recruiting clinical trials for non hodgkin lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 16. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for non hodgkin lymphoma?

non hodgkin lymphoma research spans Phase 1 (8 trials), Phase 2 (6 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a non hodgkin lymphoma clinical trial?

Eligibility criteria for non hodgkin lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

8

Phase 2

6

Phase 3

2

Top Sponsors

Paolo Caimi, MD 1 trial

New York Medical College 1 trial

He Huang 1 trial

Lyell Immunopharma, Inc. 1 trial

St. Jude Children's Research Hospital 1 trial

Recruiting Clinical Trials

NCT07225439 Phase 1

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Paolo Caimi, MD

NCT02393157 Phase 2

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

New York Medical College

NCT04227015 EARLY_Phase 1

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

NCT05826535 Phase 1, Phase 2

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

United States, Austr...

Lyell Immunopharma, Inc.

Familial Investigations of Childhood Cancer Predisposition

St. Jude Children's Research H...

NCT07195799 Phase 2

Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL

The First Affiliated Hospital ...

Lifestyle Intervention of Food and Exercise for Lymphoma Survivors

University of Miami

NCT07623850 Phase 1

A Phase I Study of JLM019 Injection

Jecho Biopharmaceuticals Co., ...

NCT02508038 Phase 1

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

University of Wisconsin, Madis...

NCT06563596 Phase 2

Epco, Zanu, Ritux for R/R FL or MZL

Reid Merryman, MD

NCT05098613 Phase 1

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

University of Colorado, Denver

NCT03223610 Phase 1, Phase 2

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

National Cancer Institute (NCI...

NCT05645107 Phase 3

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

United States, Bosni...

Grifols Therapeutics LLC

NCT06343311 Phase 1, Phase 2

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Estrella Immunopharma, Inc.

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

Memorial Sloan Kettering Cance...

NCT06395441 Phase 3

Wisconsin Ginseng for Decreasing Cancer Related Fatigue

Related Conditions

hodgkin lymphoma (5) diffuse large b cell lymphoma (3) lymphoma (3) high grade b cell lymphoma (2) follicular lymphoma (2) chronic lymphocytic leukemia (2) marginal zone lymphoma (2) burkitt lymphoma (2) acute lymphoblastic leukemia (2) relapsed non hodgkin lymphoma (2) refractory non hodgkin lymphoma (2) large b cell lymphoma (2)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology